These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 22180678)

  • 1. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
    Flies DB; Sandler BJ; Sznol M; Chen L
    Yale J Biol Med; 2011 Dec; 84(4):409-21. PubMed ID: 22180678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
    Sznol M; Chen L
    Clin Cancer Res; 2013 Mar; 19(5):1021-34. PubMed ID: 23460533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
    Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
    Front Immunol; 2020; 11():563258. PubMed ID: 33488573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
    Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 as a potential target in cancer therapy.
    McDermott DF; Atkins MB
    Cancer Med; 2013 Oct; 2(5):662-73. PubMed ID: 24403232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy.
    Giuroiu I; Weber J
    Cancer J; 2017; 23(1):23-31. PubMed ID: 28114251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
    Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
    Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
    Yan Y; Zhang L; Zuo Y; Qian H; Liu C
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
    Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
    Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
    Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
    Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant checkpoint blockade for cancer immunotherapy.
    Topalian SL; Taube JM; Pardoll DM
    Science; 2020 Jan; 367(6477):. PubMed ID: 32001626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current issues and perspectives in PD-1 blockade cancer immunotherapy.
    Chamoto K; Hatae R; Honjo T
    Int J Clin Oncol; 2020 May; 25(5):790-800. PubMed ID: 31900651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.
    Xue S; Hu M; Iyer V; Yu J
    J Hematol Oncol; 2017 Apr; 10(1):81. PubMed ID: 28388955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.